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More  robust  identification  of  putative 
molecular targets for the development of 
novel therapeutics is a logical outcome 
of  the  post-genomic  age  of  molecular 
medicine.  Undoubtedly  the  concept  of 
personalized medicine is becoming a real-
ity (Hamburg and Collins, 2010), and in 
this  scenario,  the  pharmacological  sci-
ences are ideally positioned to have a huge 
impact on the continued development of 
this field; specifically as it relates to the 
advent of mechanism-based, personalized 
therapeutics. In fact, the incredible rate of 
technology development and the parallel 
increase in our capacity to harness and 
apply  the  inordinate  amount  of  infor-
mation generated in the wake of these 
advancements creates tremendous chal-
lenges for our field, but also, enormous 
translational research opportunities.
The purpose of this article is to briefly 
review the Grand Challenge for Integrative 
and  Regenerative  Pharmacology,  and  to 
highlight how meeting the challenge will 
ensure  our  active  participation  in  this 
exciting, and quite frankly unprecedented 
era  of  translational  scientific  endeavor. 
The Grand Challenge is codified below in 
general terms, but without question it will 
require a multi/interdisciplinary collabo-
rative effort, on a global basis, to be suc-
cessful. Furthermore, it is clear that each of 
the three aspects of this Grand Challenge 
could  themselves  be  the  subject  of  an 
entire review article. Herein we provide 
only a general conceptual framework to 
familiarize the interested reader with the 
overall topic.
The Grand Challenge for Integrative and 
Regenerative Pharmacology is three-fold:
1.  To  utilize  Integrative  Pharmacology 
(studies  ranging  from  in  vivo  whole 
animal  pharmacology/toxicology  to 
complex in vitro and ex vivo systems) to 
obtain improved insight into   relevant 
mechanisms  of  end  organ/tissue 
  dysfunction (i.e., target validation) as 
well as mechanisms of tissue regenera-
tion, repair, and replacement.
2.  To  utilize  cutting  edge  drug  delivery 
technologies to improve localized deli-
very  of  therapeutic  drug  concentra-
tions/effects, and furthermore, enhance 
specificity  with  respect  to  the  cellular 
and  subcellular  targets/compartments 
of interest.
3.  To  leverage  both  1  and  2  to  create  a 
new generation of therapies for impro-
ved symptomatic treatment of disease 
(i.e.,  fewer  side/off-target  effects  due 
to  improved  MOA,  enhanced  locali-
zation,  and  cellular/subcellular  spe-
cificity),  and  moreover,  development 
of    transformational  curative  therapies 
through the establishment of the prin-
ciples of regenerative pharmacology.
Utilization of integrative 
Pharmacology StrategieS
As noted in our mission statement, the 
purpose  of  this  Specialty  Journal  is  to 
emphasize  the  importance  of  complex 
systems and whole animal research for the 
discovery of novel mechanisms of action 
and novel therapeutic entities leading to 
the  discovery  and  development  of  new 
treatments for human disease. Implicit in 
this approach is the necessity to coordinate 
information obtained in complex in vitro 
and ex vivo systems with data obtained 
on rodent and large animal models that 
recapitulate relevant aspects of the cor-
responding  human  clinical  conditions. 
Such an endeavor is intrinsically multi-
disciplinary,  and  pharmacologists  will 
need to reach out to their colleagues in 
systems  biology,  bioinformatics,  math-
ematics, engineering, etc., to be success-
ful. As recently pointed out by Dr. Michael 
Rogers at NIGMS:
“At this time, NIGMS has a substantial 
grant investment in pharmacology and 
in  systems  biology,  but  we  have  not 
seen a great deal of activity integrating 
  pharmacology with systems biology to 
benefit drug   discovery and the understand-
ing of drug action.” (https://loop.nigms.
nih.gov/index.php/2009/09/09/a-new-
frontier-for-  therapeutics-integrating-
pharmacology-and-systems-biology/).
In  this  regard,  NIGMS  has  recently 
sponsored workshops to increase awareness 
of this critical effort, and to promote the 
required scientific interactions/collabora-
tions. Further details about this important 
effort are available in a recent publication 
(Berg et al., 2010). The complexities of the 
“Integrative”  or “Systems”  pharmacology 
process are well beyond the focused nature 
of this brief report but have been elegantly 
addressed  in  another  recent  publication 
(Dollery, 2010). Importantly, the parallel 
development of novel training programs for 
preparing the next generation of researchers 
to participate in this aspect of the Grand 
Challenge has also recently been described 
(Sobie et al., 2010).
Without  question,  utilization  of  the 
resources and infrastructure resulting from 
this enormous effort represents an important 
tool with which to address this aspect of the 
Grand Challenge. Certainly, this collabora-
tive approach falls well within the scope of 
Integrative and Regenerative Pharmacology. 
Encouraging  examples  of  how  a  systems 
approach  (i.e.,  multiscale  analysis  and 
mathematical  modeling)  may  contribute 
to the development of novel therapeutics 
can be found with respect to recently pub-
lished mathematical models of integrated 
calcium homeostasis (Peterson and Riggs, 
2010), as well as with respect to the cardiac 
physiome project (Bassingthwaighte et al., 
2009). Applications even more specific to 
Integrative Pharmacology have also recently 
been reviewed (Hendriks, 2010); where the 
importance of analysis of functional pathway 
pharmacology has been emphasized. That is, 
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in thinking from developing drugs whose 
primary purpose is to treat symptoms (i.e., 
palliative) to developing drugs whose goal 
is to cure disease. This journal seems an 
ideal venue for outlining the possibilities, 
describing the journey, and publishing the 
results. The Integrative and Regenerative 
Pharmacology  specialty  journal  hopes 
to  keeps  its  finger  on  the  pulse  of  the 
  achievement of these worthy goals.
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the pursuit of Integrative and Regenerative 
Pharmacology, wherein they could be utilized 
not only to provide enhanced symptomatic 
relief of end organ disease/pathology, but to 
modulate cell and tissue formation and func-
tion as well. For example, the use of nano-
particles (both polymer and lipid based) to 
enhance delivery of both genes (Pack et al., 
2005) and other difficult to formulate/deliver 
therapeutics, such as those used for the treat-
ment of cancer (Drummond et al., 2009) have 
recently been described. Furthermore, nano-
carriers can be modified in numerous ways 
to cater to both the therapeutic indication, 
as well as the environment in the tissue of 
interest (Torchilin, 2009).
Delivery of imProveD 
SymPtomatic treatmentS anD 
tranSformative cUrative 
theraPieS
The  ultimate  goal  of  Integrative  and 
Regenerative  Pharmacology  is  improved 
therapies  for  human  disease.  The  last 
aspect  of  the  Grand  Challenge  therefore 
is to optimize the alignment of Integrative 
and Regenerative Pharmacology with mod-
ern drug delivery technologies and systems 
pharmacology approaches. This will surely 
require a paradigm shift in the way that 
integrative  pharmacologists  think  about 
developing novel therapies; specifically, a 
shift toward vastly improved symptomatic 
treatment of disease, and moreover, to the 
development of truly curative pharmaco-
therapies. For example, when there is suf-
ficient viable tissue remaining, many new 
pharmacological  strategies  that  leverage 
the newest developments in systems phar-
macology and drug delivery systems can be 
envisioned for the improved treatment of 
disease/pathology, including Regenerative 
Pharmacology. However, when there is a 
paucity of viable tissue, or none at all, tra-
ditional pharmacotherapy will not suffice, 
and other approaches, such as tissue engi-
neering and advanced regenerative medi-
cine technologies (also under the auspices 
of Regenerative Pharmacology) will need 
to be implemented.
In summary, as with all of the medical 
sciences, there are many challenges ahead in 
Integrative and Regenerative Pharmacology. 
Nonetheless, it is time for a seismic move 
that can account for the   complexity of signal 
transduction networks. The rationale for this 
latter approach is that improved target vali-
dation (and improved clinical translation of 
preclinical results) should take into account 
both  upstream  and  downstream  pathway 
events, as well as the impact of the disease 
process, per se, on the pharmacological target 
of interest. The implications of this “systems” 
approach  to  Integrative  and  Regenerative 
Pharmacology are straightforward.
imProveD Utility anD enhanceD 
SPecificity of theraPeUtic DrUg 
Delivery SyStemS
Another aspect of the Grand Challenge is the 
application  of  drug  delivery  technologies. 
Development and implementation of these 
cutting  edge  technologies  clearly  requires 
multi/interdisciplinary  collaboration.  Not 
surprisingly, modern drug delivery systems 
derive from technologies developed at the 
boundaries  of  nanotechnology,  materials 
science, chemistry, and engineering. In this 
regard,  a  systematic  and  comprehensive 
review  of  modern  drug  delivery  systems 
would be problematic even in a lengthy report 
dedicated only to that subject, in large part 
because these systems comprise a wide array 
of mostly application-specific technologies. 
Notwithstanding this, the goal of all of these 
technologies is to overcome a common set 
of barriers that limit the effectiveness of tra-
ditional  pharmacotherapy,  and  moreover, 
extend  the  realm  of  deliverable  therapeu-
tic agents to a wider array of compounds, 
as well as gene therapies. The first of these 
barriers is the issue of vascular extravasation 
(Fukumura et al., 2010). That is, ensuring 
that  the  drug/compound/gene  of  interest 
leaves the systemic circulation to enter the 
tissue(s) of interest. Of course, drug delivery 
systems that utilize transdermal, injection, or 
direct implantation routes are by definition 
less dependent on extravasation. However, 
once the compound/technology of interest 
has been delivered to the tissue of interest, 
there are still local diffusion barriers in the 
tissue, and then, there is still the issue of cel-
lular and subcellular targeting specificity. All 
of these issues are currently being addressed 
by a diverse group of labs on a worldwide 
basis. There are clearly major implications 
of the availability of these technologies to 